SPATA16

Across TCGA pan-cancer cohorts, SPATA16 RNA is linked to patient survival in 21 of 34 cancer types, making it the most broadly survival-associated SPATA16 data layer compared with 7 for mutation status.

The strongest signal is observed in mesothelioma (MESO), where higher SPATA16 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated SPATA16 expression acts as an unfavorable survival marker, although some lineages such as LUSC and PAAD show a favorable association.

MESO, KICH, and KIRC are the cancer types where SPATA16 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
MESO	OS	Tertile	II,III,IV	0.141	0.586	<.001	153	view →
KICH	DFS	Tertile	All	0.429	0.914	<.001	81	view →
KIRC	DFS	Tertile	All	0.629	0.851	<.001	80	view →
UCEC	DFS	Tertile	All	0.754	0.864	<.001	34	view →
BRCA	OS	Tertile	II,III,IV	0.920	0.965	.017	27	view →
CHOL	OS	Tertile	All	0.113	0.623	.040	18	view →
THYM	OS	Tertile	III,IV	0.615	1.000	.019	18	view →
LUSC	DFS	Tertile	II,III,IV	1.000	0.643	.001	16	view →
PAAD	OS	Quartile	II,III,IV	0.699	0.388	.022	15	view →
TGCT	DFS	Median	All	0.913	0.748	.013	12	view →
BLCA	DFS	Tertile	All	0.223	0.353	.036	12	view →
STAD	DFS	Quartile	IV	0.624	0.188	.007	10	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 21 lineages.

SPATA16–MESO (OS)

Open the MESO breakdown →